CST4 and adenocarcinoma: Furthermore, when we carried out the survival analyses in each histology subgroup, the benefit of low Cystatin SN expression was significant in patients with adenocarcinoma (DFS, 32 vs. 13 months, P = 0.004; OS, 63 vs. 24 months, P = 0.005) [Fig. 3(C–D)], whereas OS duration was similar between high and low-Cystatin SN expression subsets in SCC patients (57 vs. 46 months, P = 0.094) [Fig. 3(E–F)].